Molecular Profiles introduces nanoscale predictive analytical screening for APIs

UK contract research provider Molecular Profiles has added nanoPASS (nanoscale Predictive Analytical Screening Solution) to its comprehensive nanoscale analytical services offering.

This innovative service platform is a comprehensive suite of complementary analytical techniques designed to optimise solid state selection of APIs and provide further insight into the formulation of APIs and excipients.

Processing of drug substance and excipients can have a significant effect on surface properties and subsequent stability/bioavailability of the active. To decide on the best formulation option, full understanding of bulk and surface physicochemical properties is required. Enabling technologies allow empirical observations such as batch-to-batch variation, cohesive tendency and powder flow to be correlated to actual physicochemical properties.

The nanoPASS suite has been equipped with an extended range of analytical techniques, including nanoscale determination of materials, mechanical and cohesive properties, chemical spectroscopy, physical properties (XRPD and thermal techniques), high-resolution spatial mapping and imaging of chemical, physical, thermal and material properties.

The unique solid state characterisation capabilities of the service platform enable users to compare bulk and surface properties of drug substance, excipients, granules and aggregates, providing them with a detailed physicochemical profile.

Only small amounts of sample are required to provide precise and dependable material characterisation. According to Molecular Profiles, an example of the power of the analytical benefits afforded by nanoPASS is the pre-formulation screening of the physical properties of single formulated particles using atomic force microscopy (AFM), which provides deep insight into the pharmaceutical function of developmental products.

"The introduction of this novel service platform further demonstrates our dedication to providing a high quality and reliable extension to the r&d capabilities within pharmaceutical companies," said Dr Nikin Patel, ceo of Molecular Profiles.